H22 Mouse Liver Cancer Cell Line

Introduction

The H22 Mouse Liver Cancer Cell Line was established in 1952 from a tumor cell suspension prepared from H22 hepatocellular carcinoma solid tumors induced in C3HA mice by the Institute of Oncology of the USSR Academy of Medical Sciences. The tumor cell suspension was subsequently subcutaneously transplanted into Kunming mice, where it eventually developed into an ascites tumor model. Later, the H22 cell line was further developed and propagated by Dalian Medical University.

OriCell™ H22 Mouse Liver Cancer Cell Line is primarily used in liver cancer research, including anticancer drug screening and evaluation, as well as investigations into the mechanisms underlying tumorigenesis and progression, such as evaluating the effects of Podocarpus seed polysaccharides (PSP) on tumor growth in mice.

When citing our products in academic publications, please use the following format: "OriCell™ [Product Name] + [Catalog Number], from Cyagen Biosciences."

Product Information

QC

• Pass the detection of bacteria, fungi, mycoplasma, and endotoxins.
• Verified by cell recovery viability testing.
• Verified by STR analysis.

Please refer to "COA" for details.

General Handling Principles

• Maintain strict aseptic technique. Ensure complete sterility throughout all procedures, particularly within the laminar flow hood and incubator.
• Follow standardized protocols. Adhere strictly to the product manual. Implement rigorous control over experimental variables and include appropriate parallel controls.
• Use high-quality consumables and reagents. This product requires culture vessels suitable for adherent growth, and the reuse of these vessels is not recommended. The reagents used must be validated for reliability, cell compatibility, and batch-to-batch consistency.

Warm Notice: The cryopreservation medium of this product contains DMSO, which may pose potential risks. Please handle it with care.